Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The decrease in physical activity due to increasing dyspnoea that over time leads to a
steadily worsening condition and increasing restriction of physical functioning is a key
problem for COPD patients and affects even the early stages.
Clinical studies to investigate both Spiriva® and Striverdi® Respimat® have demonstrated a
marked improvement in physical exercise capacity.
However, there have so far been no data from the daily practice setting about everyday
functioning on combination treatment with Spiriva® Respimat® plus Striverdi® Respimat® or
Spiriva® 18 Mikrogramm plus Striverdi® Respimat® in patients requiring treatment with 2
long-acting bronchodilators.
The objective of this NIS is to measure changes in physical functioning as a surrogate for
physical activity and exercise capacity in COPD patients on treatment with Spiriva® Respimat®
plus Striverdi® Respimat® or Spiriva® 18 Mikrogramm plus Striverdi® Respimat® in routine
daily treatment (so-called real life setting).